Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages
MagnetOs is the first open fibrillar collagen matrix bone graft substitute to receive clearance to market for interb…
MagnetOs is the first open fibrillar collagen matrix bone graft substitute to receive clearance to market for interb…
Soft, moldable formulation that is ready to use with no need for thawing or mixing Becomes third commercial MagnetOs pro…
Rheinmetall has been awarded another major order for personal protective equipment for frontline medical staff and care…
ARRI verlagert Hauptsitz in die Münchner Parkstadt Schwabing Hochmodernes Produktions- und Bürogebäude mit optimalen Ar…
MagnetOs Granules and MagnetOs Putty receive TGA approval in Australia Initial launch of MagnetOs on the Australian mark…
On August 28, 2019, a ceremony was held in honor of medical technology company Richard Wolf and its Brazilian distributo…
RIWOspine GmbH, headquartered in Knittlingen, Germany, is one of the world's leading suppliers of endoscopic systems for…
Agreements in Netherlands, Switzerland and Austria and letter of intent in Finland Supports further acceleration of sale…
Global partner to market an advanced bone graft supplied by Kuros Agreement demonstrates interest of major orthobiologic…
Kuros Biosciences will this week present results from several investigator-led clinical case studies of MagnetOs Granule…